Culture

Popular breast cancer drugs don't work the way we thought they did

Some of the most commonly used drugs for treating hereditary breast and ovarian cancers may not work the way we thought they did, according to new University of Colorado Boulder research.

The paper, published February 2 in the journal Nature Communications, sheds new light on how they do work and could open the door to new next-generation medications that work better, the authors said.

"Despite the success of these drugs which sell in the billions of dollars per year and treat many thousands of patients, there are many unknowns about their potency and efficacy that if better understood could lead to improvements," said senior author Karolin Luger, a professor in the Department of Biochemistry. "Our paper provides a fuller picture."

The research centers around a class of drugs known as PARP-inhibitors, broadly prescribed to target cancers fueled by a mutation in the BRCA, or BReast CAncer, gene.

When functioning properly, the BRCA gene plays a key role in repairing damaged DNA inside cells. When the gene is mutated or missing, cancer risk rises.

About one in 10 of the quarter-million women diagnosed with breast cancer annually have a BRCA mutation. And BRCA-fueled cancers tend to come earlier, be more aggressive, and resist treatment.

Enter PARP inhibitors.

First unveiled clinically in 2014, the drugs target a ubiquitous family of proteins called PARPs (poly-ADP-ribose), which were discovered in the 1960s and are also instrumental in fixing broken DNA.

"PARPs are the first responders," explains first author Johannes Rudolph, a senior researcher in the Department of Biochemistry who worked with graduate student Genevieve Roberts on the study. "DNA damage happens, PARP goes in and finds it, and then it sends out a signal to other proteins to come in and help with repairs."

Because both PARP and BRCA also serve to repair DNA damage inside cancer cells, disabling the PARP first-responder in someone who doesn't have a functioning BRCA repair crew delivers what Rudolph describes as a lethal "double whammy" to cancer cells.

With this in mind, pharmaceutical companies have raced to develop more PARP inhibitors, with at least four in use today and others being explored to treat different forms of cancer.

But as it turns out, PARP is not acting alone.

Scientists recently discovered that another protein called HPF1 (histone PARylation Factor 1) is attached to the PARP protein at precisely the location where all the action happens, working closely with it in its role as first responder.

Existing drugs were developed long before HPF1 was even known to exist.

So Rudolph and Luger began to wonder: Does this newly-discovered co-protein influence how well those cancer drugs work? And if so, could drugs designed specifically to target it also work better?

Their findings suggest yes.

"It appears that existing drugs were designed to inhibit only two-thirds of the proteins at play here, because we didn't know this other third existed," says Rudolph.

For the new paper, Rudolph developed a new method to study just how tightly existing drugs bind to PARP inside cells - a measure of potency and efficacy - both in the presence and absence of HPF1.
In some cases, the drugs worked just as well whether it was there or not. But in others, it made a big difference.

For instance, the drug Olaparib bound more tightly and significantly longer to PARP when HPF1 was present than when it was not.

Put simply, this drug may, by sheer coincidence, impact the combination of the two proteins, making it work better. Meanwhile, for other drugs, there is likely room for improvement.

"This suggests that future PARP inhibitors should be aimed at taking advantage of this interaction in order to become more potent," Rudolph said.

Luger notes that such room for improvement is likely there for many drugs currently on the market, as drug candidates are often tested in isolation in test tubes to see if they work, but once inside the cell they interact with a complex network of proteins and enzymes that are not entirely understood.

"Drug development tends to move quickly, moving from in-vitro models to animal models to clinical trials without fully understanding the mechanism of action," she says. "That's a fine approach because it gets you there fast, but if you really want to improve upon these drugs you need to understand why and how they really work. That's what we tried to do with this paper."

Credit: 
University of Colorado at Boulder

The quick choice might be a choice-overload avoidance strategy

BUFFALO, N.Y. - A popular streaming service boasts a film inventory approaching 4,000 titles. When it's time to pick a movie, are you more likely to quickly make a decision or meticulously sift through the possibilities?

Psychologists refer to those who search minimally for something to arrive at an adequate choice as "satisficers." It's the "maximizers," meantime, who search exhaustively for what might be considered as the perfect option.

Previous studies exploring both strategies after making a choice often present satisficing as a more psychologically healthy alternative and even something to aspire to. And why not? Spending about as much time choosing a movie as it takes to actually watch it seems like the agonizing reality of someone incapable of choosing from a constellation of options.

But new research from the University at Buffalo that measured cardiovascular responses in the moment of making a choice, rather than after-the-fact, suggests the opposite: It's the satisficers who feel incapable, and what appears to be a speedy certainty might instead be a defense from having to think too deeply about the choices being presented to them.

"We might assume maximizers are having a negative experience in the moment, obsessing over the perfect choice. But it appears to be the satisficers - and that might be why they're satisficing," says Thomas Saltsman, a psychology researcher in the UB College of Arts and Sciences and the paper's lead author. "We found evidence that compared to maximizers, satisficers exhibited cardiovascular threat responses consistent with evaluating themselves as less capable of managing their choice in the moment."

The findings, published in the journal Psychophysiology, break with traditional wisdom. The implications are relevant not just to everyday decision making, but speak as well to how people approach significant choices, according to Mark Seery, an associate professor of psychology at UB, and one of the paper's co-authors.

"Anyone who has had the experience of maximizing and thought about the energy and stress saved by satisficing might want to rethink that position," says Seery. "There's a time and a place for satisficing, but people who do so as a defense against the agony of choice might not be prepared to make critical decisions when they have to."

Using a sample of 128 participants, the researchers first assessed everyone's decision-making style (maximizing vs. satisficing), before presenting them with 15 online personal profiles and accompanying cards with related biographical details. Participants had three minutes to choose their "ideal" person or partner. Afterward, they reported on their decision.

Unlike previous studies, the researchers measured cardiovascular responses to better understand participants' psychological experiences during their choice, a method Saltsman and Seery have used in previous work. In particular, they focused on how people experience two key motivational dimensions called task engagement and challenge/threat.

Task engagement describes how much people care about what they're doing, as indicated by how hard and fast the heart is pumping. Challenge/threat addresses how capable and confident someone feels in moments of stress. Confidence (challenge) causes arteries to dilate, a more efficient cardiovascular state than threat, or lack of confidence, which causes the arteries to constrict.

Saltsman says the team found no evidence that maximizers and satisficers differed in terms of task engagement, or how much importance they placed on their decisions.

"What we did find is that satisficers exhibited greater threat," he says. "It presents a novel view of satisficing, one that is more defensive, uncomfortable and reactionary in nature, rather than easy, expedient and carefree."

Saltsman says satisficers may search minimally through their options not because they are less particular or simply care less about their choices than maximizers, but because they feel incapable of choosing from so many options.

"Ultimately, whether we're the Netflix viewer who swiftly settles for the lame but relatable romantic comedy, or who scrolls endlessly through its bottomless offering list of content options, it's important to occasionally press the pause button and ask why we are approaching this decision the way we are," says Saltsman.

Credit: 
University at Buffalo

Research identifies more sustainable, cost-effective approach to treating citrus canker

image: Plant pathologists behind this research

Image: 
APS

An important bacterial disease that affects citrus trees and causes lesions, citrus canker has been effectively controlled by spraying copper. However standard management techniques involve spraying excessive amounts of copper and water without consideration for the size of the trees.

"This technique resulted in a waste of resources as well as higher costs, detrimental environmental impact, and risk for development of copper resistant strains," explained plant pathologist Franklin Behlau, who recently published an article discussing a more sustainable approach to managing citrus canker.

Behlau and his colleagues showed that it is possible to control citrus canker by spraying much less water and copper. "By adjusting both copper and water usage based on the volume of the citrus trees without affecting the quality of disease control, we have taken an important step to a more economically and environmentally sustainable citrus industry."

This research was conducted in a field trial carried out during two seasons in a commercial orchard of Pera sweet orange in Brazil. This is the first study to show that citrus canker can be managed with such a small amount of copper and water. It also identified the minimum copper deposition on the treated surface per spray necessary to protect against the disease.

"The impact for the citrus industry is huge. By using the most efficient treatments identified in our study, growers can save up 80% in the amount of copper and up to 60% in the volume of water used annually to manage citrus canker," explained Behlau. "By using less active ingredient, growers can prevent accumulation of copper in the soil and reduce the long-term effects that it may have on the development of the root system and the tree canopy."

In addition to studying citrus canker, scientists in the São Paulo state and the West-Southwest Minas Gerais state have been studying the most important diseases and pests that threaten the Brazilian citrus belt. Recent findings have been incorporated into the orchard management routine by producers, resulting in a more conscious and balanced production system.

"Our research, and the other research coming out of Brazil, can contribute significantly to a more sustainable citrus industry not only in Brazil but throughout the world. These results can help meet the global challenge of using fewer conventional pesticides in agriculture."

Credit: 
American Phytopathological Society

What the Biden-Harris administration means for chemistry

The inauguration of Joe Biden and Kamala Harris marks a new era for science policy in the U.S. and beyond. The new administration has inherited a global pandemic and worsening climate change, among other science-related issues. A cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, delves into what this means for chemists and chemistry as a whole.

One of the most pressing issues facing the Biden administration is the fight against climate change. Biden campaigned on net-zero emissions of greenhouse gases by 2050 and has laid out a sweeping plan to switch the U.S. to cleaner energy sources, which experts say would create many research and development opportunities for chemists. Although the democrats control both houses of Congress and are eager to enact legislation on clean energy and climate change, their slim majorities mean that passing these bills could prove difficult. Environmental groups are putting pressure on the Environmental Protection Agency to update regulations and fight climate change, citing new research that could help protect the public from exposure to toxic substances.

The Biden administration is also prioritizing immigration reform, which will have a marked impact on the scientific community. Biden's proposed immigration bill would provide a path to citizenship for "Dreamers," as well as allow more people to come to the U.S. to work in and study the sciences. Other regulations put in place could see the rise of gene-edited animals for food and drug production, address the issue of per- and polyflouroalkyl substances (known as PFAS) in tap water and even see chlorpyrifos -- a neurotoxic pesticide -- banned on the federal level.

Credit: 
American Chemical Society

Biodiversity is its own catalyst -- to a point

For decades, scientists have wrestled with rival theories to explain how interactions between species, like competition, influence biodiversity. Tracking microbial life across the planet, researchers from McGill University show that biodiversity does in fact foster further diversity in microbiomes that are initially less diverse. However, diversity rates plateau with increased competition for survival and space in more diverse microbiomes.

Published in eLife, the findings could help scientists better understand how microbiomes - communities of micro-organisms living together in particular habitats like humans, animals and plants or even soils and oceans - might recover from biodiversity loss.

"We know that biodiversity is important for ecosystem stability and functions, and many physical, chemical, and biological factors can affect biodiversity. Our study shows that ecological interactions are likely an important and general factor that promote diversity," says co-author Jesse Shapiro, an Associate Professor in the Department of Microbiology and Immunology at McGill University.

Disruptions such as more antibiotics in the food chain or pesticides in the soil, are having profound effects on the human microbiome and the wider microbial ecosystem of the planet. Reversing the negative consequences requires an appreciation of what has gone wrong, as well as how to put matters right. This demands a better understanding of the workings of the microbiome, say the researchers.

Do predicted patterns occur in nature, not just in the lab?

The question of whether "diversity begets diversity" has been debated for years in studies of natural plant and animal populations and bacteria evolved in the laboratory. While some scientists argue that existing biodiversity can limit more diversity as species vie for space and survival, others argue that it can promote species richness and foster coexistence among different species.

To test how ecological theory actually plays out in nature, the researchers employed massive crowd-sourced efforts to analyze DNA sequences of microbial communities in the largest survey of biodiversity on the planet. Researchers found that microbiome diversity promotes further diversity in communities like the human gut, where there is less diversity. Yet diversification slows as ecological niches are increasingly filled in more diverse communities like soils.

The challenge of occupying the same niche

Ecological niches represent the role a species plays in a community - including how it responds to resources and competitors in a given habitat. It's challenging for two species to occupy the same niche in the same habitat for a long time. Under ideal conditions, a species will thrive and play a unique role, without struggling for survival and space. This explains why diversity rates peak as ecological niches are increasingly filled in communities with more individuals and types of species.

"We now have a better understanding of how the theory of biodiversity applies to a much larger fraction of the genetic diversity on Earth," says Shapiro.

The study focuses on the accumulation of diversity by way of migration: new types of bacteria arriving into one environment from another. In the future, the researchers plan to extend their study to evolutionary diversification, including mutation and gene gain or loss, and how it is affected by local biodiversity.

Credit: 
McGill University

New ink jet approach offers simple way to print microdisk lasers for biosensing

image: A new inkjet printing method can be used to fabricate tiny biocompatible polymer microdisk lasers for biosensing. The new approach allows fabrication in a room temperature, open-air environment.

Image: 
Hiroaki Yoshioka, Kyushu University

WASHINGTON -- Researchers have developed a unique inkjet printing method for fabricating tiny biocompatible polymer microdisk lasers for biosensing applications. The approach enables production of both the laser and sensor in a room temperature, open-air environment, potentially enabling new uses of biosensing technologies for health monitoring and disease diagnostics.

"The ability to use an inexpensive and portable commercial inkjet printer to fabricate a sensor in an ambient environment could make it possible to produce biosensors on-site as needed," said research team leader Hiroaki Yoshioka from Kyushu University in Japan. "This could help make biosensing widespread even in economically disadvantaged countries and regions, where it could be used for simple biochemical tests, including those for pathogen detection."

In The Optical Society (OSA) journal Optical Materials Express, the researchers describe the ability to print microdisk lasers as small as the diameter of a human hair from a specially developed polymer called FC-V-50. They also show that the microdisks can successfully be used for biosensing with the widely used biotin-avidin system.

"Our technique can be used to print on almost any substrate," said Yoshioka. "This means that it could one day be possible to print a sensor for health monitoring directly on the surface of a person's fingernail, for example."

Eliminating the heat

Many of today's biosensors use the strong interaction between the molecules biotin and avidin to detect the presence of proteins that indicate infection or disease. This typically involves tagging a molecule of interest with biotin and then detecting when avidin binds to it.

One way to measure biotin-avidin binding is to add a biotin-labeled protein to the surface of an optical microcavity that acts like a miniature laser. When avidin binds to the biotin on the microcavity, its optical properties change enough to shift light emission in a way that can be used to detect binding.

However, the modification process needed to add biotin to the surface of microcavities is tedious and time-consuming. It also requires high-temperature heat treatments that aren't compatible with all materials, such as polymers.

"We developed an organic microdisk optical cavity laser for biosensing using FC-V-50," said Yoshioka. "This special inkjet polymer has a carboxyl functional group that is compatible with biotin, which eliminates the need for any type of heat treatment."

Printing sensors

To produce microdisk lasers, the researchers developed an ink that contained FC-V-50 and a laser dye. A piezo element embedded in an inkjet nozzle about the size of a hair allows a single, tiny ink droplet to be ejected when a voltage is applied. Once dry, this printed drop will emit light when excitation light is applied. As the light travels along the inside circumference of the disk it is amplified to generate laser light.

To turn the microdisk laser into a sensor, the researchers printed a microdisk using their inkjet method and then added reagents that allowed biotin to immobilize on its surface at room temperature. They then used light to excite the microdisk laser under a microscope and measured the reference laser emission spectrum. Next, they poured the avidin solution onto the surface of the microdisk and washed away any that didn't bind to the biotin. The laser emission was measured again to see how it deviated from the reference spectrum.

To test the method, the researchers fabricated biosensors and measured their ability to detect streptavidin protein at different concentrations. They were able to detect a maximum mode shift of 0.02 nanometers for a 0.1 parts per million concentration of streptavidin. Now that they have demonstrated the ability to print functioning biosensors, they plan to further evaluate and optimize sensor performance. Portable devices for measuring the light emission would also need to be developed for the sensors to be used at the point of care.

Credit: 
Optica

Fungus that eats fungus could help coffee farmers

image: Coffee leaf infected by the coffee leaf rust (orange spores) and the hyperparasite (white spores).

Image: 
Beyene Zewdie

Coffee rust is a parasitic fungus and a big problem for coffee growers around the world. A study in the birthplace of coffee - Ethiopia - shows that another fungus seems to have the capacity to supress the rust outbreaks in this landscape.

"Coffee leaf rust is a fungal disease that is a problem for coffee growers around the world, especially on Arabica coffee, which accounts for three quarters of global coffee production and has the finest cup quality. There is a need to learn more about natural solutions instead of just applying pesticides," says Kristoffer Hylander, professor at the Department of Ecology, Environment and Plant Sciences (DEEP) at Stockholm University.

Coffee leaf rust is caused by a parasitic fungus that attacks the leaves of the coffee shrub. In some areas it has previously been known to have a potential natural enemy - a hyperparasitic fungus that grows on top of the rust. However, very little is known about its biology and to what extent it could suppress the rust. This is the first study on the interaction between the rust and its hyperparasite in Ethiopia, the birthplace of Arabica coffee. The coffee plant, the rust and its hyperparasite may have coevolved in Ethiopia for a long time.

Coffee leaf rust generally increases in abundance from the rainy to the dry season. However, it seems like this increase is reduced in places where the hyperparasite is common:

"This is an indication that the hyperparasite may have the potential to reduce outbreaks of the rust in areas where both the rust and the hyperparasite exist together," says Ayco Tack, associate professor at the Department of Ecology, Environment and Plant Sciences (DEEP) at Stockholm University.

It seems like the rust and the hyperparasite thrive in slightly different environments, with the rust adapting well in less humid places and the hyperparasite favouring slightly more humid places such as coffee farms with more shade trees.

"This could be a win-win situation. By increasing the tree cover in coffee plantations with native shade tree species that maintain their leaves during the dry season, we could perhaps benefit both biodiversity and the hyperparasite," says Kristoffer Hylander, professor at the Department of Ecology, Environment and Plant Sciences (DEEP) at Stockholm University.

The authors did not investigate whether the presence of the hyperparasite could lead to better coffee yields, via its effect on rust. The hyperparasite might reduce leaf drop associated with severe rust infection, thus reducing the expected indirect negative effect of the rust on coffee yields.

"This would be one of the next important steps in this research, since yield of coffee (or revenue) matters most for the smallholder coffee farmers. Interestingly, Ethiopia does not seem to have as big a problem with coffee leaf rust as other coffee-producing countries - and it would be interesting to find out if the hyperparasite may be an explanation for this difference. It is also important to note that the effect of coffee leaf rust in this landscape might change with the current global climate change," says Beyene Zewdie, who recently defended his thesis on the ecology of coffee diseases in Ethiopia at the Department of Ecology, Environment and Plant Sciences (DEEP) at Stockholm University.

More detailed experimental studies are needed to explore the relationships between the rust and the hyperparasite. This could enable coffee growers to utilize the hyperparasite as a biological control for the coffee leaf rust in more intensively managed plantations where the rust epidemics are highly problematic.

Credit: 
Stockholm University

State-funded pre-K may enhance math achievement

In the first longitudinal study to follow Georgia pre-K students through middle school, Stacey Neuharth-Pritchett, associate dean for academic programs and professor in UGA's Mary Frances Early College of Education, found that participating in pre-K programs positively predicted mathematical achievement in students through seventh grade.

"Students who participated in the study were twice as likely to meet the state standards in their mathematics achievement," said Neuharth-Pritchett. "School becomes more challenging as one progresses through the grades, and so if in middle school, students are still twice as likely to meet the state standards, it's clear that something that happened early on was influencing their trajectory."

The study found that, in fourth through seventh grades, the odds of a pre-K participant in the study meeting Georgia's state academic standards on the statewide standardized test were 1.67-2.10 times greater than the odds for a nonparticipant, providing evidence of sustained benefits of state-funded pre-K programs.

"Pre-K is a critical space where children experience success, and it sets them on a trajectory for being successful as they make the transition to kindergarten," she said. "The hope is that when children are successful early in school, they are more likely to be engaged as they progress and more likely to complete high school."

Although quality learning experiences during the early years of development have been shown to provide the skills and knowledge for later mathematics achievement, access and entry to high-quality preschool programs remain unequal across the nation.

"Our study looked at a high-needs school district that enrolled children from vulnerable situations in terms of economics and access to early learning experiences," said Neuharth-Pritchett. "A number of the children in the study had not had any other formative experiences before they went to kindergarten."

Educational experiences are seen as foundational to later school success with some studies documenting other beneficial outcomes for students who attend pre-K, including a higher chance to complete high school, less mental health concerns, less reliance on the welfare system and more. However, students from low-income families often have more limited opportunities to learn at home as well as in pre-K programs.

While some families are knowledgeable about providing their children with basic mathematical concepts and other foundational skills for a smooth home to school entry, other families might not be aware of the expectations for having mastered a number of these foundational skills before entering kindergarten.

"Equal access to pre-K education has a long history that goes all the way back to the war on poverty. Part of the thinking during the 1960s was that such early learning opportunities would provide the high-quality preschool education that could level the educational playing field between those with economic resources and those without," she said. "Our study indicated sustained benefits for children's early learning experiences that persist into the elementary and middle school years."

Some implications of the study for policymakers to consider include ensuring more equitable access to pre-K programs and hiring highly skilled teachers to promote children's learning and development. More than half of the pre-K teachers involved in the study held either a master's or specialist degree, indicating the importance and influence of high-quality, experienced instructors on children's academic success.

Because of a change in program support for the Georgia Prekindergarten Program during Gov. Nathan Deal's term, a high proportion of pre-K teachers are now very early in their teaching careers.

Along with Jisu Han, an assistant professor at Kyung Hee University and co-author of the study, Neuharth-Pritchett plans to continue following the study's participants as they progress through high school.

"The state of Georgia invests substantial resources into this program, so it's good that these outcomes can be cited for its efficacy," said Neuharth-Pritchett. "The data from this study gives a much more longitudinal view of success and suggests these programs contribute to children's education and success. Our results ultimately contribute to evidence supporting early learning and factors influencing long-term academic success for Georgia's children."

Credit: 
University of Georgia

Study reveals neurons responsible for rapidly stopping behaviors, actions

image: Ueli Rutishauser, PhD

Image: 
Cedars-Sinai

LOS ANGELES (Feb. 3, 2021) -- For the first time in humans, investigators at Cedars-Sinai have identified the neurons responsible for canceling planned behaviors or actions--a highly adaptive skill that when lost, can lead to unwanted movements.

Known as "stop signal neurons," these neurons are critical in powering someone to stop or abort an action they have already put in process.

"We have all had the experience of sitting at a traffic stop and starting to press the gas pedal but then realizing that the light is still red and quickly pressing the brake again," said Ueli Rutishauser, PhD, professor of Neurosurgery, Neurology and Biomedical Sciences at Cedars-Sinai and senior author of the study published online in the peer-reviewed journal Neuron. "This first-in-human study of its kind identifies the underlying brain process for stopping actions, which remains poorly understood."

The findings, Rutishauser said, reveals that such neurons exist in an area of the brain called the subthalamic nucleus, which is a routine target for treating Parkinson's disease with deep brain stimulation.

Patients with Parkinson's disease, a motor system disorder affecting nearly 1 million people in the U.S., suffer simultaneously from both the inability to move and the inability to control excessive movements. This paradoxical mix of symptoms has long been attributed to disordered function in regions of the brain that regulate the initiation and halting of movements. How this process occurs and what regions of the brain are responsible have remained elusive to define despite years of intensive research.

Now, a clearer understanding has emerged.

Jim Gnadt, PhD, program director for the NIH Brain Research through Advancing Innovative Technologies® (BRAIN) Initiative, which funded this project, explained that this study helps us understand how the human brain is wired to accomplish rapid movements.

"It is equally important for motor systems designed for quick, fast movements to have a 'stop control' available at a moment's notice--like a cognitive change in plan--and also to keep the body still as one begins to think about moving but has yet to do so."

To make their discovery, the Cedars-Sinai research team studied patients with Parkinson's disease who were undergoing brain surgery to implant a deep brain stimulator--a relatively common procedure to treat the condition. Electrodes were lowered into the basal ganglia, the part of the brain responsible for motor control, to precisely target the device while the patients were awake.

The researchers discovered that neurons in one part of the basal ganglia region--the subthalamic nucleus--indicated the need to "stop" an already initiated action. These neurons responded very quickly after the appearance of the stop signal.

"This discovery provides the ability to more accurately target deep brain stimulation electrodes, and in return, target motor function and avoid stop signal neurons," said Adam Mamelak, MD, professor of Neurosurgery and co-first author of the study.

Mamelak notes that many patients with Parkinson's disease have issues with impulsiveness and the inability to stop inappropriate actions. As a next step, Mamelak and the research team will build on this discovery to investigate whether these neurons also play a role in these more cognitive forms of stopping.

"There is strong reason to believe that they do, based on significant literature linking inability to stop to impulsiveness," said Mamelak. "This discovery will enable investigating whether the neurons we discovered are the common mechanisms that link the two phenomena."

Clayton Mosher, PhD, co-first author of the study and a project scientist in the Rutishauser lab, says while it has long been hypothesized that such neurons exist in a particular brain area, such neurons had never been observed "in action" in humans.

"Stop neurons responded very quickly following the onset of the stop cue on the screen, a key requirement to be able to suppress an impending action," said Mosher. "Our result is the first single-neuron demonstration in humans of signals that are likely carried by this particular pathway."

Credit: 
Cedars-Sinai Medical Center

First-in-human clinical trial confirms HIV vaccine approach by IAVI and Scripps Research

video: A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. In this video, William Schief, Ph.D., discusses the trial results and the vaccine design.

Image: 
Scripps Research

NEW YORK and LA JOLLA, CA--A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.

"This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well," says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center, whose laboratory developed the vaccine. "With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens."

Schief presented the results on behalf of the study team at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference today.

The study sets the stage for additional clinical trials that will seek to refine and extend the approach--with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.

HIV, which affects more than 38 million people globally, is known to be among the most difficult viruses to target with a vaccine, in large part because it constantly evolves into different strains to evade the immune system.

"These exciting findings emerge from remarkably creative, innovative science and are a testament to the research team's talent, dedication and collaborative spirit, and to the generosity of the trial participants," says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. "Given the urgent need for an HIV vaccine to rein in the global epidemic, we think these results will have broad implications for HIV vaccine researchers as they decide which scientific directions to pursue. The collaboration among individuals and institutions that made this important and exceptionally complex clinical trial so successful will be tremendously enabling to accelerate future HIV vaccine research."

One in a million

For decades now, HIV researchers have pursued the holy grail of stimulating the immune system to create rare but powerful antibodies that can neutralize diverse strains of HIV. Known as "broadly neutralizing antibodies," or bnAbs, these specialized blood proteins could attach to HIV spikes, proteins on the virion surface that allow the virus to enter human cells, and disable them via important yet difficult-to-access regions that don't vary much from strain to strain.

"We and others postulated many years ago that in order to induce bnAbs, you must start the process by triggering the right B cells--cells that have special properties giving them potential to develop into bnAb-secreting cells," Schief says. "In this trial, the targeted cells were only about one in a million of all naïve B cells. To get the right antibody response, we first need to prime the right B cells. The data from this trial affirms the ability of the vaccine immunogen to do this."

The priming step would be the first stage of a multi-step vaccine regimen aimed at eliciting many different types of bnAbs, he says.

Promise beyond HIV

The strategy of targeting naïve B cells with specific properties is called "germline-targeting," as these young B cells display antibodies encoded by unmutated, or "germline" genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.

"This is a tremendous achievement for vaccine science as a whole," says Dennis Burton, Ph.D., professor and chair of the Department of Immunology and Microbiology at Scripps Research, scientific director of the IAVI Neutralizing Antibody Center and director of the NIH Consortium for HIV/AIDS Vaccine Development. "This clinical trial has shown that we can drive immune responses in predictable ways to make new and better vaccines, and not just for HIV. We believe this type of vaccine engineering can be applied more broadly, bringing about a new day in vaccinology."

The clinical trial, IAVI G001, was sponsored by IAVI and took place at two sites: George Washington University (GWU) in Washington, D.C., and the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle, enrolling 48 healthy adult volunteers. Participants received either a placebo or two doses of the vaccine compound, eOD-GT8 60mer, along with an adjuvant developed by the pharmaceutical company GSK. Julie McElrath, M.D., Ph.D., senior vice president and director of Fred Hutch's Vaccine and Infectious Disease Division, and David Diemert, M.D., professor of medicine at GWU School of Medicine and Health Sciences, were lead investigators at the trial sites.

"This is a landmark study in the HIV vaccine field, demonstrating success in the first step of a pathway to induce broad neutralizing antibodies against HIV-1," McElrath says. "The novel design of the immunogen, the clinical trial and the molecular B cell analyses provide a roadmap to accelerate further progress toward an HIV vaccine."

Wide network of collaborators

Funding from the Bill & Melinda Gates Foundation, through the Collaboration for AIDS Vaccine Discovery, supported a wide network of partners conducting complex analyses.

The critical assay used to judge the vaccine candidate, epitope-specific single B cell sorting and B cell receptor (BCR) sequencing, was developed and carried out by teams at the NIH Vaccine Research Center, led by Adrian McDermott, Ph.D. (chief of the Vaccine Immunology Program), Richard Koup, M.D. (deputy director and chief of the Immunology Laboratory and Immunology Section), and research scientist David Leggat, Ph.D.; and at Fred Hutch, led by McElrath and senior staff scientist Kristen Cohen, Ph.D. Study design and data analysis were led by staff scientists Allan deCamp, Ph.D., Greg Finak, Ph.D., and Jimmy Fulp at the Vaccine Immunology Statistical Center at Fred Hutch, with assistance from the Schief lab.

Credit: 
Scripps Research Institute

Study examines role of biomarkers to evaluate kidney injury in cancer patients

ROCHESTER, Minn. -- A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.

"Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer," says Sandra Herrmann, M.D., a Mayo Clinic nephrologist and the study's senior author. "In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis."

Dr. Herrmann says a kidney biopsy is the gold standard to diagnose this condition. However, a kidney biopsy is an invasive procedure that some patients may not be able to undergo because of the risk of bleeding.

"Our study provides important, first-time data for clinicians and patients on the use of biomarkers to routinely evaluate the cause of acute kidney injury in patients undergoing immune checkpoint inhibitor therapy for cancer," says Dr. Herrmann. "These biomarkers could assist with helping doctors discriminate treatment associated kidney injury from other causes and may also help aid clinical decision-making related to whether immune checkpoint inhibitor therapy should be continued if the injury found is not related to immunotherapy."

For this study, researchers followed patients who were seen at Mayo Clinic for acute kidney injury from 2014 to 2020. They found that blood markers of kidney function and inflammation, serum creatinine and C-reactive protein, respectively, as well as urine markers ? urine retinol binding protein-to-urine creatinine ratio ? were significantly higher in patients with acute kidney injury due to interstitial nephritis associated with immune checkpoint inhibitor therapy when compared to other patients treated with immunotherapy but with acute kidney injury due to other causes, such as acute tubular necrosis associated with other cancer therapies.

"Being able to tell if acute kidney injury in a cancer patient is due to a certain type of cancer therapy without the need for an invasive test is extremely important," says Dr. Herrmann. "It simplifies the work-up for patients, makes the approach safer and quicker, and helps physicians better guide patients through their care."

Dr. Herrmann says that being able to attribute acute kidney failure to a cause other than immune checkpoint inhibitor therapy allows patients to continue with their cancer immunotherapy, which can be lifesaving. In addition, she says acute kidney failure has profound prognostic implications for patients and needs to be properly treated, so promptly identifying the cause is important.

Credit: 
Mayo Clinic

New clues to how muscle wasting occurs in people with cancer

UNIVERSITY PARK, Pa. -- Muscle wasting, or the loss of muscle tissue, is a common problem for people with cancer, but the precise mechanisms have long eluded doctors and scientists. Now, a new study led by Penn State researchers gives new clues to how muscle wasting happens on a cellular level.

Using a mouse model of ovarian cancer, the researchers found that cancer progression led to fewer skeletal muscle ribosomes -- particles in the cell that make proteins. Because muscle mass is mainly determined by protein synthesis, having less ribosomes likely explains why muscles waste away in cancer.

Gustavo Nader, associate professor of kinesiology and physiology at Penn State, said the findings suggest a mechanism for muscle wasting that could be relevant not just for people with cancer, but other conditions as well.

"Loss of muscle mass is also associated with the aging process, malnutrition, and people with COVID-19 and HIV-AIDS, among others," Nader said. "Not only is muscle wasting a common problem, but there's currently no cure or treatment, either. But now that we understand the mechanism better, we can move forward with trying to find ways to reverse that mechanism."

According to the researchers, significant muscle wasting -- or "cachexia" -- occurs in about 80% of people with cancer and is responsible for about 30% of cancer deaths. It's also associated with a reduced quality of life, problems tolerating chemotherapy and lower survival rates. According to Nader, "cachexia is often the killer, not the tumor."

Nader said that because there is no current cure or treatment for cachexia, it is vital for scientists to understand precisely how and why it happens. But while there has been a lot of research trying to understand and prevent the mechanism that causes muscles to waste, Nader and his team wanted to tackle the problem from a new angle.

"Most of the focus has been on protein degradation, where people have tried to block proteins from being chopped up, or degraded, in order to prevent the loss of muscle mass," Nader said. "But many of those efforts have failed, and one reason may be because people forgot about the protein synthesis aspect of it, which is the process of creating new proteins. That's what we tackled in this study."

For the study, the team used a pre-clinical mouse model of ovarian cancer with significant muscle loss. By using mice, the researchers were able to study the progression of cancer cachexia over time which would be difficult to do with human patients.

After analyzing their results, the researchers found that mice with tumors experienced a rapid loss of muscle mass and a dramatic reduction in the ability to synthesize new proteins, which can be explained by a drop in the amount of ribosomes in their muscles.

"So we cracked the first layer of this problem, because we showed that there are less ribosomes and less protein synthesis," Nader said.

Then, the researchers set out to explain why the number of ribosomes was decreased. After examining the ribosomal genes, they found that once a tumor was present, the expression of the ribosomal genes started to decrease until it reached a level that made it impossible for the muscles to produce enough ribosomes to maintain enough protein synthesis to prevent muscle loss.

Nader said that while more research is needed, he hopes the findings -- recently published in the Federation of American Societies for Experimental Biology Journal -- can eventually contribute to prevent people from losing muscle mass and function.

"If we can better understand how muscles make ribosomes, we will be able to find new treatments to both stimulate muscle growth and prevent muscle wasting," Nader said. "This is especially important considering that current approaches to block tumor progression target the ribosomal production machinery, and because these drugs are given systemically, they will likely affect all tissues in the body and will also impair muscle building."

Credit: 
Penn State

How does pain experienced in everyday life impact memory?

How do the normal pains of everyday life, such as headaches and backaches, influence our ability to think? Recent studies suggest that healthy individuals in pain also show deficits in working memory, or the cognitive process of holding and manipulating information over short periods of time. Prior research suggests that pain-related impairments in working memory depend on an individual's level of emotional distress. Yet the specific brain and psychological factors underlying the role of emotional distress in contributing to this relationship are not well understood.

A new study, titled "Modeling neural and self-reported factors of affective distress in the relationship between pain and working memory in healthy individuals," and published in the journal Neuropsychologia sought to address this gap in the literature. The study was authored by recent University of Miami psychology Ph.D. graduate students Steven Anderson, Joanna Witkin, and Taylor Bolt and their advisors Elizabeth Losin, director of the Social and Cultural Neuroscience Laboratory at the University of Miami; Maria Llabre, professor and associate chair of the Department of Psychology; and Claire Ashton-James, senior lecturer at the University of Sydney.

The study used publicly available brain imaging and self-report data from the Human Connectome Project (HCP), a large-scale project sponsored by the National Institutes of Health (NIH) which aims to construct a map of the complete structural and functional connections in the healthy human brain. Brain imaging and self-report data from 416 HCP participants were analyzed using structural equation modeling (SEM), a statistical technique for modeling complex relationships between multiple variables. In the 228 participants who reported experiencing some level of pain in the 7 days prior to the study, the authors found that higher pain intensity was directly associated with worse performance a commonly used test of working memory, the n-back task. In the n-back task, participants are shown a series of letters and asked whether the letter they are seeing appeared some number of screens previously. The more screens back in the sequence participants are asked to recall, the more working memory is required.

In addition, the authors found that higher pain intensity was indirectly associated with worse working memory performance through increased activity in a particular region in the center of the frontal cortex during the n-back task, the ventromedial prefrontal cortex (vmPFC). The vmPFC is a brain region involved in pain, affective distress, and cognition. Interestingly, the relationship between everyday pain and vmPFC brain activity in this study is similar to prior findings in patients with chronic pain.

"We found that healthy participants with even low levels of reported pain had different levels of activity in the vmPFC during the n-back task compared to healthy participants who didn't report pain. Surprisingly, this pattern of activity was more similar to patients with chronic pain than healthy patients who are exposed to pain manipulations in a laboratory," said Witkin.

In contrast, the authors found that certain aspects of emotional distress reported by participants, such as anger, fear, and perceived stress, were not associated with working memory performance.

"Studies looking at the relationship between pain and cognition have typically focused on patients with chronic pain or research participants given experimentally-induced pain," noted Anderson. "Even though pain is a common experience for many people, we know surprisingly little about how the everyday experience of pain impacts cognition."

Using the publicly available HCP dataset allowed the researchers to include data from a much larger group of participants than is typical in brain imaging studies due to the high cost of brain scans. This large sample enabled authors to use structural equation modeling, a statistical technique that allows for the understanding of complex relationships between multiple variables that in this case may help explain how pain decreases working memory. The authors note that their findings have potential implications in both clinical and non-clinical settings.

"This study highlights the real impact that pain can have on our ability to think even in healthy people, and points how this may come about in the brain," said Losin.

Credit: 
University of Miami

Urban agriculture in Chicago does not allow consumers to rely solely on local food

Environmentally conscious consumers try to "buy local" when food shopping. Now, a study of food raised around Chicago has shown that buying local can't provide all necessary nutrients for area residents, though it could fulfill their needs if some nutrients were supplied as supplements. The researchers report in ACS' Environmental Science & Technology that urban agriculture made little difference in reducing overall land area, and thus distance, required to supply all nutritional needs.

As the U.S. population continues to flow to urban regions, consumers are moving farther from farms and croplands. This limits nutrient recycling and drives up emissions associated with transporting food. In addition, urban centers can develop "food deserts" where residents can't purchase nutritious food close to home. One potential solution is urban agriculture, which repurposes space within cities -- such as vacant lots and rooftops -- to grow crops. Christine Costello and colleagues wanted to know the impact of urban agriculture on enabling people living within a range of distances from Chicago's center to eat local food, yet meet their complete nutritional needs.

The team considered 28 nutrients, the amount of available land, a variety of crops and livestock, a range of crop yields and both conventional and urban agriculture in the analysis. They drew circles on a map around Chicago with increasing radii, up to 400 miles, the maximum distance the U.S. government deems "local." Within that perimeter around Chicago, no mix of locally raised crops and livestock could satisfy all nutritional needs of the population. However, if D and B12 vitamins could be provided as supplements, a radius as small as 65 miles was sufficient. Urban agriculture could provide an important nutritional benefit by increasing diet diversity and availability of fresh fruits and vegetables. But it would only slightly reduce the radius (and land area) needed for supplying nearly complete nutrition locally, the researchers say.

Credit: 
American Chemical Society

Standard water treatment technique removes and inactivates an enveloped virus

image: An enveloped virus, Φ6 (left), clumps together and becomes damaged by conventional iron coagulation (right). Scale bar, 100 nm.

Image: 
Adapted from <i>Environmental Science & Technology</i> <b>2021</b>, DOI: 10.1021/acs.est.0c07697

Enveloped viruses have been detected in raw sewage and sludge, but scientists still don't fully understand the fate and infectivity of these viruses during water purification at treatment plants. Now, researchers reporting in ACS' Environmental Science & Technology have discovered that a standard water treatment technique, called iron (III) coagulation, and its electrically driven counterpart, iron (0) electrocoagulation, can efficiently remove and inactivate a model enveloped virus.

Enveloped viruses have an outer coating of lipids and proteins that helps protect their genetic material. Typically, disrupting this coat inactivates the virus. Until now, most studies have investigated only disinfection by chlorine or ultraviolet light as a means to control enveloped viruses in wastewater. However, particles suspended in the water can sometimes shield viruses from disinfectants. Shankar Chellam and colleagues wondered whether a different method called coagulation with iron (III), which is already widely applied during water treatment, can remove and inactivate enveloped viruses. They also wanted to study a related technique, iron (0) electrocoagulation, that shows promise for small-scale water treatment. As a model enveloped virus, the researchers chose an RNA virus, called Φ6, that infects bacteria.

The researchers treated a solution containing Φ6 with either iron (III) or with iron (0) electrocoagulation, both of which formed iron precipitates. The hydrophobic viral envelopes stuck to the precipitates, allowing Φ6 to be easily removed as the solids settled. The conventional coagulation reduced the amount of active virus in the water by more than 100,000 times in 2.6 minutes, whereas electrocoagulation was slower but about 10 times more effective. The researchers observed that the structures of most of the viral particles in the iron precipitates were damaged, which rendered them unable to infect their host bacteria. Electrocoagulation also oxidized lipids in the viral envelope, further inactivating Φ6. These results suggest that water treatment plants are already well equipped to remove enveloped viruses from drinking water by iron (III) coagulation, and viral levels are likely even further reduced by the additional treatment steps of filtration and disinfection, the researchers say.

Credit: 
American Chemical Society